Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026

CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that third quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, November 5th.

GlobeNewsWire • Oct 12, 2026

Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers

CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the publication of previously released results from PREPARE1, a prospective, multicenter, randomized controlled trial (RCT) evaluating PuraPly®AM (PCMP) plus standard of care (SoC) compared to SoC alone in hard-to-heal diabetic foot ulcers (DFUs). The trial achieved its primary endpoint, and the results published in the Journal of Wound Care demonstrate statistically significant improvements in wound closure at 12 weeks among patients treated with PuraPly®AM plus SoC, providing clinical evidence supporting the use of PuraPly®AM in one of the most costly and difficult-to-treat chronic wound populations.

GlobeNewsWire • Oct 12, 2026

These beaten-down stocks could bounce back in January, if history is any guide

Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year

Market Watch • Sep 21, 2026

Organogenesis Q2 Earnings Call Highlights

Organogenesis NASDAQ: ORGO reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for Medicare & Medicaid Services, while management pointed to sequential improvement in product sales and market share gains.

MarketBeat • Aug 7, 2026

Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript

Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2026.

GlobeNewsWire • Aug 6, 2026

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced published results from a prospective, multicenter, randomized controlled trial (RCT) evaluating Affinity plus standard of care (SoC) compared to SoC alone in the management of complex venous leg ulcers (VLUs). The results were published in the Journal of Wound Care demonstrating statistically significant improvements in wound closure at weeks 12 and 16 for the Affinity + SoC group across two wound duration strata studied, providing compelling new peer-reviewed evidence for one of the most difficult-to-treat wound populations in chronic wound care.

GlobeNewsWire • Jul 27, 2026

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that second quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, August 6th.

GlobeNewsWire • Jul 9, 2026

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that the U.S. Food and Drug Administration (FDA) has completed their filing determination and accepted for review the Company's Biologics License Application (BLA) for ReNu®, a cryopreserved, amniotic suspension allograft developed for the treatment of pain in symptomatic knee osteoarthritis (OA).

GlobeNewsWire • Jul 6, 2026

Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked

Organogenesis is grappling with significant revenue declines in 2026 due to adverse Medicare policy changes impacting its core skin substitute products. 2025 marked a peak year for ORGO, but 2026 guidance now calls for a 45–52% year-over-year revenue drop to $270–310 million. Market headwinds have intensified, with clinicians in some cases moving away from skin substitutes entirely, compounding ORGO's challenges.

Seeking Alpha • Jun 15, 2026